仁度生物发布新平台 切入肿瘤筛查赛道

Core Insights - The company has achieved a breakthrough in research and development with the successful creation of a new technology platform called "Digital SAT + Fully Automated Equipment DigiNAT," which surpasses existing digital PCR technology in sensitivity, ease of use, and speed of detection [2] - The platform opens new pathways for precise RNA quantification detection and is expected to be applied in areas such as early cancer screening, infectious disease detection, and personalized medicine [2] - The company has initiated the development of RNA digital precision quantification detection products, focusing on urinary system tumor screening products for prostate cancer and bladder cancer [2] - The company is actively pursuing intellectual property protection around its core technology, with several domestic and international invention patents applied for, some of which have already been granted [2] - Additionally, the company's self-developed Chlamydia (CT) and Human Papillomavirus (HPV) testing reagents have successfully passed EU regulatory agency review and obtained IVDRCE certification, facilitating future international collaborations and expansion of overseas sales networks [2]